AltruBio Taiwan Inc.
Update：2023/06/12
Industries
Main Industry
Health Care
Main Product/Service
AltruBio’s lead drug candidates are PSGL-1 agonist antibodies serving as immune checkpoint enhancers: ALTB-168, their first-generation molecule, has demonstrated safety and efficacy in Phase 1 and Phase 2 trials; and the next-generation ALTB-268, a tetrav
Founded Year
2020
Unified Business No.
82948968
Status
Active
Number of Employees
0
Total Paid-in
Capital
25,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Exclusive content for members
Members-only content. Please log in to access.
Introduction
AltruBio Inc. is a clinical-stage biotechnology company headquartered in San Francisco with an R&D center in Taipei. They specialize in developing first-in-class immune checkpoint enhancers (ICEs) for immunological and inflammatory diseases, backed by a w
